Physician profile
Fang Li
NPI 1356447841
$3,793.05
in general payments reported to CMS, 2019-2025
29 companies · $348 in 2025
The $348 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $564 · 2021: $1,412 · 2022: $131 · 2023: $206 · 2024: $546 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.44 |
| Education | $254.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $536.04 | 2019-2024 | |
| Lundbeck LLC | $357.80 | 2021-2025 | Vyepti |
| Jazz Pharmaceuticals INC. | $300.63 | 2019-2024 | Xywav |
| Alexion Pharmaceuticals, INC. | $298.79 | 2020-2024 | Ultomiris |
| Abbvie INC. | $283.07 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $256.13 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $236.07 | 2020-2021 | |
| Amgen INC. | $130.32 | 2019-2020 | |
| Genzyme Corporation | $128.38 | 2025 | |
| Sk Life Science, INC. | $122.84 | 2020-2025 | |
| Neurocrine Biosciences, INC. | $117.43 | 2021 | |
| Nuvasive, INC. | $115.39 | 2019 | |
| Biogen, INC. | $109.83 | 2021 | |
| Janssen Pharmaceuticals, INC | $106.29 | 2021 | |
| Amneal Pharmaceuticals LLC | $100.68 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $96.75 | 2019-2021 | |
| Lilly USA, LLC | $88.35 | 2019 | |
| Mallinckrodt Enterprises LLC | $79.73 | 2019 | |
| Livanova USA, INC. | $70.11 | 2020-2022 | |
| Pfizer INC. | $34.97 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $34.02 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $32.00 | 2019-2020 | |
| Celgene Corporation | $30.42 | 2022-2023 | Zeposia |
| Ucb, INC. | $29.72 | 2024 | Briviact |
| Genentech USA, INC. | $27.00 | 2021-2022 | |
| Csl Behring | $19.92 | 2021 | |
| Impel Pharmaceuticals INC. | $18.70 | 2022 | |
| Tg Therapeutics, INC. | $16.59 | 2024 | |
| Almatica Pharma LLC | $15.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fang Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.